a phase III study of lenalidomide plus rituximab UGent Bibliougent.be
biblio.ugent.be
von JP Leonard · · Zitiert von: 292 — Leonard, John P, Marek Trneny, Koji Izutsu, Nathan H Fowler, Xiaonan Hong, Jun Zhu, Huilai Zhang, Fritz Offner, Adriana Scheliga, Grzegorz S ...
Comparison of efficacy and safety of ripertamab (SCT400) ...John Wiley
onlinelibrary.wiley.com
von Y Shi · · Zitiert von: 3 — Xiaonan Hong,. Xiaonan Hong. Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. von J Zhu · — Xiaonan Hong,. Xiaonan Hong. Fudan University Cancer Hospital, Shanghai, China. Search for more papers by this author.
End of treatment PET-CT predicts progression free survival ...PosterSessionOnline
www.postersessiononline.eu
von L Kostakoglu · Zitiert von: 4 — ... Kostakoglu,1 Maurizio Martelli,2 David Belada,3 Angelo-Michele Carella,4 Neil Chua,5 Eva Gonzalez-Barca,6 Xiaonan Hong,7 Antonio Pinto,8 Laurie H Sehn,9.
Total metabolic tumor volume as a survival predictor for ...Haematologica
haematologica.org
von L Kostakoglu · · Zitiert von: 18 — Chiara Ghiggi,6 Neil Chua,7 Eva González-Barca,8 Xiaonan Hong,9. Antonio Pinto,10 Yuankai Shi,11. Yoichi Tatsumi,12 Christopher Bolen,13 Andrea Knapp,2 Gila ...
A phase 3 study of rituximab biosimilar HLX01 in patients with ...BioMed Central
jhoonline.biomedcentral.com
von Y Shi · · Zitiert von: 22 — Xiaonan Hong. Daping Hospital, Third Affiliated Hospital of the Army Medical University, Chongqing, China. Dong Wang.
Phase I dose-escalating study of 24-h continuous infusion ...CORE
core.ac.uk
von B Wang · · Zitiert von: 10 — Biyun Wang · Wen Zhang · Xiaonan Hong ·. Ye Guo · Jin Li. Received: 24 December Accepted: 2 March Published online: 15 March
Phase I dose-escalating study of 24-h continuous infusion ...Springer
link.springer.com
von B Wang · · Zitiert von: 10 — Biyun Wang, Wen Zhang, Xiaonan Hong, Ye Guo & Jin Li. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai...
Alle Infos zum Namen "Xiaonan Hong"
A Chinese subgroup analysis of the phase III PHOENIX trialNational Institutes of Health (.gov)
pubmed.ncbi.nlm.nih.gov
von J Zhu · — Jun Zhu , Xiaonan Hong , Yu Qin Song , Brendan Hodkinson , Sriram Balasubramanian , Songbai Wang , Qingyuan Zhang , Yuankai Shi , Huiqiang ... von GS Nowakowski · · Zitiert von: 116 — ... Annalisa Chiappella , Randy D Gascoyne , David W Scott , Qingyuan Zhang , Wojciech Jurczak , Muhit Özcan , Xiaonan Hong , Jun Zhu ...
A Phase III Study of Lenalidomide Plus Rituximab Versus ...ASCO Journals
ascopubs.org
von JP Leonard · · Zitiert von: 292 — Xiaonan Hong , MD Collection and assembly of data: John P. Leonard, Marek Trneny, Koji Izutsu, Nathan H. Fowler, Xiaonan Hong, Jun Zhu, ...
A Phase III study of lenalidomide plus rituximab versus ...elsevierpure.com
mayoclinic.elsevierpure.com
von JP Leonard · · Zitiert von: 292 — John P. Leonard, Marek Trneny, Koji Izutsu, Nathan H. Fowler, Xiaonan Hong, Jun Zhu, Huilai Zhang, Fritz Offner, Adriana Scheliga, Grzegorz S. Nowakowski, ...
Bortezomib plus rituximab versus ...muni.cz
www.muni.cz
von B Coiffier · · Zitiert von: 114 — OSMANOV, Xiaonan HONG, Adriana SCHELIGA, Jiří MAYER, Fritz OFFNER, Simon RULE, Adriana TEIXEIRA, Jan WALEWSKI, Sven DE VOS, Michael CRUMP, Ofer SHPILBERG, Dixie ...
Efficacy and safety of obinutuzumab for the first-line ...MedNexus
mednexus.org
von X Hong · · Zitiert von: 1 — Xiaonan Hong, Yuqin Song, Yuankai Shi, Qingyuan Zhang, Wei Guo, Gang Wu, Junmin Li, Jifeng Feng, Anastasiia Kinkolykh, Andrea Knapp, ...
Efficacy of Paclobutrazol and Gibberellin4+7 on Growth ...ASHS
journals.ashs.org
von MJ Sarmiento · · Zitiert von: 19 — Xiaonan Hong et al., Chinese Medical Journal, Alterations in intestinal microbiota composition coincide with impaired intestinal morphology and ...
Ibrutinib plus Bendamustine and Rituximab in Untreated ...lu.se
portal.research.lu.se
von ML Wang · · Zitiert von: 49 — ... Olivier Hermine, José Ángel Hernández-Rivas, Xiaonan Hong, Seok Jin Kim, David Lewis, Yuko Mishima, Muhit Özcan, Guilherme F. Perini, ...
Ofatumumab Versus Rituximab Salvage ...Europe PMC
europepmc.org
von GW van Imhoff · · Zitiert von: 191 — ... Sungkyunkwan University School of Medicine, Seoul, Korea; Xiaonan Hong, Fudan University, Shanghai, China; Jette Soenderskov Goerloev, Rigshospitalet; ...
Ofatumumab Versus Rituximab Salvage ...rug.nl
research.rug.nl
von GW van Imhoff · · Zitiert von: 192 — ... WonSeog Kim, Xiaonan Hong, Jette Soenderskov Goerloev, Andrew Davies, Maria Dolores Caballero Barrigon, Michinori Ogura, Sirpa Leppa, ...
Randomized phase III trial of ibrutinib and rituximab plus ...University of Southampton
eprints.soton.ac.uk
von A Younes · · Zitiert von: 384 — Anas Younes · Laurie H Sehn · Peter Johnson · ORCID iD · Pier Luigi Zinzani · Xiaonan Hong · Jun Zhu · Caterina Patti · David Belada.
Thalidomide enhanced the efficacy of CHOP ...Oncotarget
www.oncotarget.com
von D Ji · · Zitiert von: 13 — ... Qiu Li, Junning Cao, Ye Guo, Fangfang Lv, Xiaojian Liu, Biyun Wang, Leiping Wang, Zhiguo Luo, Jianhua Chang, Xianghua Wu, Xiaonan Hong.
Verwandte Suchanfragen zu Xiaonan Hong
| Adriana Scheliga Dong Wang |
Person "Hong" (2) Vorname "Xiaonan" (18) Name "Hong" (3443) |
sortiert nach Relevanz / Datum